论文部分内容阅读
目的:研究生长抑素受体(SSTR)在原发性乳腺浸润性癌组织中的表达情况,以及与临床病理因素的关系。方法:应用免疫组化法检测82例原发性乳腺浸润性导管癌组织中SSTR的表达,分析其与临床病理因素的关系。结果:原发性乳腺浸润性导管癌组织中SSTR阳性表达率为74.4%(61/82)。SSTR阳性表达强度与年龄(P=0.881)、肿瘤大小(P=0.522)无关,但不同病理分期(P<0.001)、分化程度(P=0.021)的肿瘤组织其SSTR表达强度有显著性差异。结论:原发性乳腺浸润性导管癌组织中SSTR阳性表达率为74.4%,因此,对大多数疑为乳腺癌的患者可应用核素显像技术(SRS)进行筛选。
Objective: To investigate the expression of somatostatin receptor (SSTR) in primary breast invasive carcinoma and its relationship with clinicopathological factors. Methods: The immunohistochemical method was used to detect the expression of SSTR in 82 cases of primary invasive ductal breast carcinoma and its relationship with clinicopathological parameters was analyzed. Results: The positive rate of SSTR in primary breast invasive ductal carcinoma was 74.4% (61/82). The positive expression of SSTR had no correlation with age (P = 0.881) and tumor size (P = 0.522), but there was a significant difference in SSTR expression between different pathological stages (P <0.001) and differentiation (P = 0.021) CONCLUSION: The positive rate of SSTR in primary invasive ductal breast carcinoma is 74.4%. Therefore, most patients suspected of breast cancer can be screened by radionuclide imaging (SRS).